OBJECTIVE: The impact of short-term analytical treatment interruptions (ATI) on the levels of cellular HIV and of residual activation after subsequent antiretroviral therapy (ART)-mediated plasma HIV viral load re-suppression remains under active investigation. DESIGN: Peripheral blood mononuclear cells (PBMC) from 23 ART-suppressed, chronically HIV-1-infected patients were evaluated at the initiation of an ATI, during ATI, and following plasma re-suppression of HIV with ART. METHODS: T-cell activation was measured by flow cytometry. Total cellular HIV DNA, and episomal 2-long terminal repeat (2-LTR) circles were measured by droplet digital PCR (ddPCR). Cellular HIV multiply spliced RNA (tat/rev), unspliced (gag), and poly(A) tailed transcripts [poly(A)] were measured by reverse transcriptase-ddPCR. Analyses were performed using R version 2.5.1 or JMP Pro 11. RESULTS: ATI (median ATI duration, 4 weeks) resulted in a rise of plasma HIV RNA (median = 72900 copies/ml), decrease in CD4+ T cells/μl (median = 511.5 cells/μl; P = 0.0001), increase in T-cell activation, and increase in cellular HIV DNA and RNA. Mean fluorescence intensity of CD38 on CD4+HLA-DR+ T cells at baseline was positively associated with total HIV DNA levels during ATI (pol: P = 0.03, Rho = 0.44). Upon ART resumption, plasma HIV re-suppression occurred after a median of 13 weeks and resulted in restoration of pre-ATI CD4+ T cells/μl, T-cell activation, and levels of cellular HIV DNA and RNA. CONCLUSION: Monitored viremia and immune activation during an ATI in ART-suppressed chronic HIV-infected patients does not change the amount of persistent cellular HIV RNA or total HIV DNA after ART-mediated re-suppression.
OBJECTIVE: The impact of short-term analytical treatment interruptions (ATI) on the levels of cellular HIV and of residual activation after subsequent antiretroviral therapy (ART)-mediated plasma HIV viral load re-suppression remains under active investigation. DESIGN: Peripheral blood mononuclear cells (PBMC) from 23 ART-suppressed, chronically HIV-1-infectedpatients were evaluated at the initiation of an ATI, during ATI, and following plasma re-suppression of HIV with ART. METHODS: T-cell activation was measured by flow cytometry. Total cellular HIV DNA, and episomal 2-long terminal repeat (2-LTR) circles were measured by droplet digital PCR (ddPCR). Cellular HIV multiply spliced RNA (tat/rev), unspliced (gag), and poly(A) tailed transcripts [poly(A)] were measured by reverse transcriptase-ddPCR. Analyses were performed using R version 2.5.1 or JMP Pro 11. RESULTS:ATI (median ATI duration, 4 weeks) resulted in a rise of plasma HIV RNA (median = 72900 copies/ml), decrease in CD4+ T cells/μl (median = 511.5 cells/μl; P = 0.0001), increase in T-cell activation, and increase in cellular HIV DNA and RNA. Mean fluorescence intensity of CD38 on CD4+HLA-DR+ T cells at baseline was positively associated with total HIV DNA levels during ATI (pol: P = 0.03, Rho = 0.44). Upon ART resumption, plasma HIV re-suppression occurred after a median of 13 weeks and resulted in restoration of pre-ATICD4+ T cells/μl, T-cell activation, and levels of cellular HIV DNA and RNA. CONCLUSION: Monitored viremia and immune activation during an ATI in ART-suppressed chronic HIV-infectedpatients does not change the amount of persistent cellular HIV RNA or total HIV DNA after ART-mediated re-suppression.
Authors: Liang Shan; S Alireza Rabi; Gregory M Laird; Evelyn E Eisele; Hao Zhang; Joseph B Margolick; Robert F Siliciano Journal: J Virol Date: 2013-03-27 Impact factor: 5.103
Authors: Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels Journal: J Infect Dis Date: 1999-04 Impact factor: 5.226
Authors: Nancie M Archin; Manzoor Cheema; Daniel Parker; Ann Wiegand; Ronald J Bosch; John M Coffin; Joseph Eron; Myron Cohen; David M Margolis Journal: PLoS One Date: 2010-02-23 Impact factor: 3.240
Authors: Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht Journal: Blood Date: 2004-04-29 Impact factor: 22.113
Authors: Sara Gianella; Christy M Anderson; Susanna R Var; Michelli F Oliveira; Steven M Lada; Milenka V Vargas; Marta Massanella; Susan J Little; Douglas D Richman; Matthew C Strain; Josué Pérez-Santiago; Davey M Smith Journal: J Virol Date: 2016-03-28 Impact factor: 5.103
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Matthew C Strain; Steven M Lada; Tiffany Luong; Steffney E Rought; Sara Gianella; Valeri H Terry; Celsa A Spina; Christopher H Woelk; Douglas D Richman Journal: PLoS One Date: 2013-04-03 Impact factor: 3.240
Authors: Erin D Huiting; Kathleen Gittens; J Shawn Justement; Victoria Shi; Jana Blazkova; Erika Benko; Colin Kovacs; Paul A Wender; Susan Moir; Michael C Sneller; Anthony S Fauci; Tae-Wook Chun Journal: J Infect Dis Date: 2019-06-19 Impact factor: 5.226
Authors: Christina K Psomas; Sarah Fidler; Malcolm Macartney; Richard Jeffreys; Lisa Reilly; Simon Collins; Santiago Moreno; Jean-Pierre Routy; Alexander Pasternak; Sabine Kinloch-de Loës Journal: J Virus Erad Date: 2018-10-01